Advertisement

Administration of natural astaxanthin increases serum HDL-cholesterol and adiponectin in subjects with mild hyperlipidemia

  • Hiroshi Yoshida
    Correspondence
    Corresponding author at: Department of Laboratory Medicine, Jikei University Kashiwa Hospital, 163-1 Kashiwashita, Kashiwa, Chiba 277-8567, Japan. Tel.: +81 4 7164 1111x2270; fax: +81 4 7164 1126.
    Affiliations
    Department of Laboratory Medicine, Jikei University Kashiwa Hospital, Chiba, Japan

    Internal Medicine of Metabolism and Nutrition, Graduate School of Medicine, Jikei University, Tokyo, Japan
    Search for articles by this author
  • Hidekatsu Yanai
    Affiliations
    Internal Medicine of Metabolism and Nutrition, Graduate School of Medicine, Jikei University, Tokyo, Japan

    Division of General Medicine, Department of Internal Medicine, Jikei University Kashiwa Hospital, Chiba, Japan
    Search for articles by this author
  • Kumie Ito
    Affiliations
    Internal Medicine of Metabolism and Nutrition, Graduate School of Medicine, Jikei University, Tokyo, Japan

    Division of General Medicine, Department of Internal Medicine, Jikei University Kashiwa Hospital, Chiba, Japan
    Search for articles by this author
  • Yoshiharu Tomono
    Affiliations
    Department of Nutrition, Jikei University Kashiwa Hospital, Chiba, Japan
    Search for articles by this author
  • Takashi Koikeda
    Affiliations
    Shiba Palace Clinic, Tokyo, Japan
    Search for articles by this author
  • Hiroki Tsukahara
    Affiliations
    Life Science Division, Fuji Chemical Industry, Japan
    Search for articles by this author
  • Norio Tada
    Affiliations
    Internal Medicine of Metabolism and Nutrition, Graduate School of Medicine, Jikei University, Tokyo, Japan

    Division of General Medicine, Department of Internal Medicine, Jikei University Kashiwa Hospital, Chiba, Japan
    Search for articles by this author

      Abstract

      Background

      Astaxanthin has been reported to improve dyslipidemia and metabolic syndrome in animals, but such effects in humans are not well known.

      Methods

      Placebo-controlled astaxanthin administration at doses of 0, 6, 12, 18 mg/day for 12 weeks was randomly allocated to 61 non-obese subjects with fasting serum triglyceride of 120–200 mg/dl and without diabetes and hypertension, aged 25–60 years.

      Results

      In before and after tests, body mass index (BMI) and LDL-cholesterol were unaffected at all doses, however, triglyceride decreased, while HDL-cholesterol increased significantly. Multiple comparison tests showed that 12 and 18 mg/day doses significantly reduced triglyceride, and 6 and 12 mg doses significantly increased HDL-cholesterol. Serum adiponectin was increased by astaxanthin (12 and 18 mg/day), and changes of adiponectin correlated positively with HDL-cholesterol changes independent of age and BMI.

      Conclusions

      This first-ever randomized, placebo-controlled human study suggests that astaxanthin consumption ameliorates triglyceride and HDL-cholesterol in correlation with increased adiponectin in humans.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Matsuzawa Y.
        • Funahashi T.
        • Kihara S.
        • Shimomura I.
        Adiponectin and metabolic syndrome.
        Arterioscler Thromb Vasc Biol. 2004; 24: 29-33
        • Zimmet P.
        • Magliano D.
        • Matsuzawa Y.
        • Alberti G.
        • Shaw J.
        The metabolic syndrome: a global public health problem and a new definition.
        J Atheroscler Thromb. 2005; 12: 295-300
        • Kadowaki T.
        • Yamauchi T.
        • Kubota N.
        • et al.
        Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome.
        J Clin Invest. 2006; 116: 1784-1792
        • Okamoto Y.
        • Kihara S.
        • Funahashi J.
        • Matsuzawa Y.
        • Libby P.
        Adiponectin: a key adipocytokine in metabolic syndrome.
        Clin Sci. 2006; 110: 267-278
        • Yoshida H.
        • Hirowatari Y.
        • Kurosawa H.
        • Tada N.
        Implications of decreased serum adiponectin for type IIb hyperlipidaemia and increased cholesterol levels of very-low-density lipoprotein in type II diabetic patients.
        Clin Sci. 2005; 109: 297-302
        • Schulze M.B.
        • Rimm E.B.
        • Shai I.
        • Rifai N.
        • Hu F.B.
        Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes.
        Diabetes Care. 2004; 27: 1680-1687
        • Pashkow F.J.
        • Watumull D.G.
        • Campbell C.L.
        Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease.
        Am J Cardiol. 2008; 101: 58D-68D
        • Iwamoto T.
        • Hosoda K.
        • Hirano R.
        • et al.
        Inhibition of low density lipoprotein oxidation by astaxanthin.
        J Atheroscler Thromb. 2000; 7: 216-222
        • Hussein G.
        • Nakagawa T.
        • Goto H.
        • et al.
        Astaxanthin ameliorates features of metabolic syndrome in SHR/NDmer-cp.
        Life Sci. 2007; 80: 522-529
        • Ikeuchi M.
        • Koyama T.
        • Takahashi J.
        • Yazawa K.
        Effects of astaxanthin in obese mice fed a high-fat diet.
        Biosci Biotechnol Biochem. 2007; 71: 893-899
        • Movva R.
        • Rader D.J.
        Laboratory assessment of HDL heterogeneity and function.
        Clin Chem. 2008; 54: 788-800
        • Kontush A.
        • Guérin M.
        • Chapman M.J.
        Spotlight on HDL-raising therapies: insights from the torcetrapib trials.
        Nat Clin Pract Cardiovasc Med. 2008; 5: 329-336
        • Qiao L.
        • Zou C.
        • Van der Westhuyzen D.R.
        • Shao J.
        Adiponectin reduces serum triglyceride by increasing VLDL triglyceride catabolism.
        Diabetes. 2008; 57: 1824-1833
        • Chan D.C.
        • Barrett P.H.
        • Ooi E.M.
        • et al.
        Very-low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-1 kinetics in obese and non-obese men.
        J Clin Endocrinol Metab. 2009; 94: 989-997
        • Tsubakio-Yamamot K.
        • Matsuura F.
        • Koseki M.
        • et al.
        Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages.
        Biochem Biophys Res Commun. 2008; 375: 390-394